ProCE Banner Activity

CheckMate 067: Long-term Survival and HRQoL With First-line Nivolumab ± Ipilimumab in Advanced Melanoma at 7.5-Yr Follow-up

Slideset Download
Conference Coverage
With 7.5-year follow-up, the phase III CheckMate 067 trial continued to demonstrate durable survival benefits with first-line nivolumab + ipilimumab in patients with advanced melanoma.

Released: June 16, 2022

Expiration: June 15, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab